USE OF CHIGLITAZAR AND RELATED COMPOUNDS Russian patent published in 2022 - IPC A61K31/403 A61P29/00 A61P9/10 A61P13/12 A61P11/00 A61P1/16 

FIELD: pharmaceutics.

SUBSTANCE: invention relates to the use of chiglitazar or its pharmaceutically acceptable salts for the manufacture of a drug for the treatment of fibrotic diseases, including fibrotic diseases caused by damage to tissue cells as a result of chronic inflammation, such as systemic scleroderma, chronic nephritis and kidney fibrosis, myelofibrosis, idiopathic pulmonary fibrosis and non-alcoholic fatty liver infiltration, as well as for the manufacture of a fibroblast inhibitor, for the manufacture of an inhibitor of mediated TGFß activation of extracellular matrix of fibroblasts, for the manufacture of an inflammatory factor inhibitor in the manufacture of a monocyte chemotaxis inhibitor. Compared with the known starting compounds, chiglitazar demonstrates more significant and different activity characteristics and has a better potential for use in the treatment of fibrotic disease.

EFFECT: expansion of the range of drugs against fibrotic diseases.

8 cl, 10 dwg, 4 tbl, 6 ex